Hold Rating on Sarepta Therapeutics Amid Regulatory Challenges and Clinical Concerns

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on SRPT stock, giving a Hold rating on August 7.

Claim 55% Off TipRanks

Anupam Rama has given his Hold rating due to a combination of factors impacting Sarepta Therapeutics. The recent regulatory challenges and media scrutiny surrounding Elevidys, a key product for Sarepta, have created a volatile environment that requires time to stabilize. This uncertainty makes it difficult to predict the near-term performance of the stock, thus warranting a cautious approach.
Anupam Rama also considers the potential of Elevidys in the Duchenne Muscular Dystrophy market. While there is enthusiasm for its use, particularly among ambulatory patients, the need to restore confidence among stakeholders remains. Additionally, the occurrence of liver enzyme elevations in some patients presents a clinical challenge that needs to be addressed. These factors collectively contribute to the decision to maintain a Hold rating on SRPT shares.

In another report released on August 7, BMO Capital also reiterated a Hold rating on the stock with a $50.00 price target.